Precipio Inc. Common Stock (PRPO)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with business quality and price. Precipio is a 61-employee diagnostics firm selling blood-cancer tests and tools such as HemeScreen and IV-Cell. Revenue has grown: $15.4M in fiscal year 2023, ended 2023-12-31; $18.6M in fiscal year 2024, ended 2024-12-31; and $24.2M in fiscal year 2025, ended 2025-12-31. Losses shrank from $5.9M in fiscal year 2023 to $4.3M in fiscal year 2024 to $363,000 in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $7.0M and net loss was $219,000; fiscal Q3 2025, the quarter ended 2025-09-30, lost $79,000; fiscal Q2 2025, the quarter ended 2025-06-30, earned $74,000. That is progress, but not a proven earnings record. The Lynch category is none because there has been a loss in each of the last four years. Financial health is mixed: debt-to-equity is 0.24 and trailing free cash flow is $789,000, a 2.0% FCF yield, but the Altman Z-score is -2.77 and EV/EBITDA is 60.85. Piotroski is 6/9. At the 2026-10-13 close of $22.59, market cap was $40.4M; FairStock calculations show P/B 2.74, ROE -8.98%, ROCE -4.81%, and P/E -36.44. The price is not a Graham bargain; it assumes a turnaround. The moat is not visible: small scale, no long profit history, and reliance on adoption of diagnostic panels. I would need consistent net income and free cash flow before seeing a margin of safety.

In plain English: Precipio is a small healthcare company that provides cancer tests and lab products, mainly for blood cancers. Sales have grown and its losses have shrunk, but it has not made a yearly profit in the last four years and a bankruptcy-risk measure is weak. At $22.59, the stock looks expensive compared with earnings, though it has a small amount of positive cash flow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer